Market Research Logo

Diagnostics and Therapeutics for Autism Spectrum Disorders: Global Markets

Diagnostics and Therapeutics for Autism Spectrum Disorders: Global Markets

The global autism spectrum disorders (ASD) market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%.

This report provides:

An overview of the regional and global markets for Autism Spectrum Disorder (ASD) therapies and diagnostics.

Analyses of global market trends, with data from 2013, 2014, and projections of compound annual growth rates (CAGRs) through 2019.

An overview of ASDs including types, epidemiology, symptoms, and causes and pathophysiology.

Coverage of approved therapies and tolerated off-label alternative treatments for ASD.

In-depth analysis of the ASD therapies market dynamics, specifically growth drivers, inhibitors, and opportunities.

A relevant patent analysis including patents nearing expiration, and recently issued patents.

Comprehensive profiles of major players in the field.


The scope of this study encompasses the global and regional markets for therapeutic and diagnostic technologies of ASD. BCC Research analyzed each market and its applications, regulatory environment, technology, market projections and market share. Issues discussed include the major drug profiles, technological features and trends. The global markets for the ASD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Spain, Italy and Japan. The markets of the rest of the world are not reported due to their economic insignificance for this report.

CHAPTER 1 INTRODUCTION
STUDY OBJECTIVES
REASONS FOR DOING THE STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
INFORMATION SOURCES AND TECHNOLOGY BENCHMARKING
FORECASTING METHODOLOGY
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL ASD MARKET, THROUGH 2019 ($ MILLIONS)
SUMMARY FIGURE GLOBAL ASD MARKET, 2013-2019 ($ MILLIONS)
CHAPTER 3 OVERVIEW
DEFINITION OF AUTISM
BACKGROUND OF AUTISM
WHY IS AUTISM A 'SPECTRUM' DISORDER?
CORE SYMPTOMS OF ASD
NON-CORE SYMPTOMS OF ASD
ETIOLOGY OF ASD
GENETIC FACTORS
NEUROCHEMICAL FACTORS
ENVIRONMENTAL FACTORS
EPIDEMIOLOGY OF ASD
SEX RATIO
AGE
PREVALENCE
HERITABILITY
COMORBIDITY
TABLE 1 ASD-ASSOCIATED COMORBIDITIES AND THEIR PREVALENCE RATES
SUBTYPE
SEVERITY
STANDARDS FOR THE DIAGNOSIS AND TREATMENT OF ASD
SCREENING AND DIAGNOSIS OF ASD
PHARMACEUTICAL TREATMENT OF ASD
ASD-LABELED PHARMACEUTICALS
OFF-LABEL PHARMACEUTICALS
Antipsychotics
Psychostimulants
Antidepressants
Antiepileptic Drugs
Antihypertensives
Sleep Medications
Antianxiety Medications
OPPORTUNITIES IN PHARMACEUTICAL DEVELOPMENT
CHAPTER 4 REGULATORY LANDSCAPE
TABLE 2 LIST OF PEDIATRIC LABEL REVISIONS FOR APPROVED AND OFF-LABEL
DRUGS USED ON ASD POPULATIONS
TABLE 3 LIST OF ISSUED SAFETY WARNINGS FOR APPROVED AND OFF-LABEL
PHARMACEUTICALS USED ON ASD POPULATIONS
TABLE 4 LIST OF DRUGS UNDER PEDIATRIC INVESTIGATION
CHAPTER 5 GLOBAL MARKETS
TABLE 5 GLOBAL ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
FIGURE 1 GLOBAL ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
THERAPEUTICS MARKET
OVERVIEW
GLOBAL ASD THERAPEUTICS MARKET BY LABEL INFORMATION
TABLE 6 GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, THROUGH 2019 ($ MILLIONS)
FIGURE 2 GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, 2013-2019 ($ MILLIONS)
ASD-labeled Pharmaceuticals
Off-label Pharmaceuticals
GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS
TABLE 7 GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ MILLIONS)
FIGURE 3 GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ MILLIONS)
Antipsychotics
TABLE 8 GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
FIGURE 4 GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
Psychostimulants
TABLE 9 GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
FIGURE 5 GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
Antidepressants
TABLE 10 GLOBAL ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
FIGURE 6 GLOBAL ANTIDEPRESSANTS MARKET FOR ASD POPULATIONS, 2013 ($ MILLIONS)
Antiepileptics
TABLE 11 GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
FIGURE 7 GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
Antihypertensives
TABLE 12 GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
FIGURE 8 GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
Sleep Medications
TABLE 13 GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
FIGURE 9 GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
Other
TABLE 14 GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
FIGURE 10 GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
Novel Therapeutic Classes
TABLE 15 GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
FIGURE 11 GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
GLOBAL ASD THERAPEUTICS MARKET BY INDICATION
TABLE 16 GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
FIGURE 12 GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, 2013-2019 ($ MILLIONS)
Irritability
TABLE 17 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, THROUGH 2019 ($ MILLIONS)
FIGURE 13 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, 2013-2019 ($ MILLIONS)
ADHD
TABLE 18 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, THROUGH 2019 ($ MILLIONS)
FIGURE 14 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, 2013 ($ MILLIONS)
Aggression
TABLE 19 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, THROUGH 2019 ($ MILLIONS)
FIGURE 15 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, 2013-2019 ($ MILLIONS)
Seizures
TABLE 20 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, THROUGH 2019 ($ MILLIONS)
FIGURE 16 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, 2013-2019 ($ MILLIONS)
Anxiety and Mood Disorders
TABLE 21 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, THROUGH 2019 ($ MILLIONS)
FIGURE 17 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOODDISORDERS, 2013-2019 ($ MILLIONS)
Sleeping Disorders
TABLE 22 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, THROUGH 2019 ($ MILLIONS)
FIGURE 18 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, 2013-2019 ($ MILLIONS)
Extrapyramidal Symptoms
TABLE 23 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, THROUGH 2019 ($ MILLIONS)
FIGURE 19 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, 2013-2019 ($ MILLIONS)
ASD (Core Symptoms)
TABLE 24 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), THROUGH 2019 ($ MILLIONS)
FIGURE 20 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), 2013-2019 ($ MILLIONS)
GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION
TABLE 25 GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, THROUGH 2019 ($ MILLIONS)
FIGURE 21 GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, 2013-2019 ($ MILLIONS)
Dopamine and Serotonin Pathway Targeting Drugs
TABLE 26 GLOBAL ASD THERAPEUTICS MARKET FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, THROUGH 2019 ($ MILLIONS)
FIGURE 22 GLOBAL ASD THERAPEUTICS FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, 2013-2019 ($ MILLIONS)
Adrenergic Receptor Targeting Drugs
TABLE 27 GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2019 ($ MILLIONS)
FIGURE 23 GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2013-2019 ($ MILLIONS)
GABAA Pathway Targeting Drugs
TABLE 28 GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, THROUGH 2019 ($ MILLIONS)
FIGURE 24 GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, 2013-2019 ($ MILLIONS)
Drugs with Other Mechanisms of Action
TABLE 29 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, THROUGH 2019 ($MILLIONS)
FIGURE 25 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, 2013-2019 ($ MILLIONS)
Drugs with Novel Mechanisms of Action
TABLE 30 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, THROUGH 2019 ($MILLIONS)
FIGURE 26 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, 2013-2019 ($ MILLIONS)
GLOBAL ASD THERAPEUTICS BY COMPANY
FIGURE 27 GLOBAL ASD THERAPEUTICS MARKET BY COMPANY, FOR 2014 (%)
GLOBAL ASD DIAGNOSTICS MARKET
OVERVIEW
TABLE 31 GLOBAL ASD DIAGNOSTICS MARKET, THROUGH 2019 ($ MILLIONS)
FIGURE 28 GLOBAL ASD DIAGNOSTICS MARKET, 2013-2019 ($ MILLIONS)
TECHNOLOGIES
MARKET
TABLE 32 GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, THROUGH 2019 ($ MILLIONS)
FIGURE 29 GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, 2013-2019 ($ MILLIONS)
Low Imbursement Group
TABLE 33 GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, THROUGH 2019 ($ MILLIONS)
FIGURE 30 GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, 2013-2019 ($ MILLIONS)
Moderate Imbursement Group
TABLE 34 GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, THROUGH 2019 ($ MILLIONS)
FIGURE 31 GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, 2013-2019 ($ MILLIONS)
High Imbursement Group
TABLE 35 GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, THROUGH 2019 ($ MILLIONS)
FIGURE 32 GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, 2013-2019 ($ MILLIONS)
CONCLUDING REMARKS
GLOBAL ASD MARKET DRIVERS AND RESTRAINTS
DRIVERS
RESTRAINTS
GLOBAL ASD MARKETS BY GEOGRAPHICAL REGION
TABLE 36 GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 33 GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, 2013-2019 ($ MILLIONS)
CHAPTER 6 MARKETS IN NORTH AMERICA
FIGURE 34 ASD PREVALENCE RATES IN NORTH AMERICA, 2000-2013 (PER 10,PEOPLE)
TABLE 37 NORTH AMERICAN ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
FIGURE 35 NORTH AMERICAN ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
THERAPEUTICS MARKET
OVERVIEW
TABLE 38 NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
FIGURE 36 NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
ASD THERAPEUTICS MARKETS IN NORTH AMERICA BY THERAPEUTIC
CLASS
TABLE 39 NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ THOUSANDS)
FIGURE 37 NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ THOUSANDS)
Antipsychotics
TABLE 40 NORTH AMERICAN ANTIPSYCHOTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 38 NORTH AMERICAN ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Psychostimulants
TABLE 41 NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONSBY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 39 NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Antidepressants
TABLE 42 NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 40 NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Antiepileptics
TABLE 43 NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 41 NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Antihypertensives
TABLE 44 NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 42 NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Sleep Medications
TABLE 45 NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 43 NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Other
TABLE 46 NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 44 NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Novel
TABLE 47 NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 45 NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
NORTH AMERICAN ASD DIAGNOSTICS MARKETS
OVERVIEW
MARKET
FORECAST
TABLE 48 NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
FIGURE 46 NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
NORTH AMERICAN ASD MARKET BY COUNTRY
TABLE 49 NORTH AMERICAN ASD MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
FIGURE 47 NORTH AMERICAN ASD MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
CHAPTER 7 MARKETS IN EUROPE
FIGURE 48 ASD COMBINED PREVALENCE RATES IN EU5 COUNTRIES, 2000 TO (PER 10,000 PEOPLE)
TABLE 50 EU5 ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
FIGURE 49 EU5 ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
THERAPEUTICS MARKET
OVERVIEW
TABLE 51 EU5 ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019 ($
MILLIONS)
FIGURE 50 EU5 ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
ASD THERAPEUTICS MARKETS IN EU5 BY THERAPEUTIC CLASS
TABLE 52 EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ THOUSANDS)
FIGURE 51 EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013 ($ THOUSANDS)
Antipsychotics
TABLE 53 EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 52 EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Psychostimulants
TABLE 54 EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 53 EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Antidepressants
TABLE 55 EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 54 EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Antiepileptics
TABLE 56 EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 55 EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Antihypertensives
TABLE 57 EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 56 EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Sleep Medications
TABLE 58 EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 57 EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
Other
TABLE 59 EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
FIGURE 58 EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
EU5 ASD DIAGNOSTICS MARKETS
OVERVIEW
FORECAST
TABLE 60 EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
FIGURE 59 EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
EU5 ASD MARKET BY COUNTRY
TABLE 61 EU5 ASD MARKETS BY COUNTRY, THROUGH 2019 ($ MILLIONS)
FIGURE 60 EU5 ASD MARKETS BY COUNTRY, 2013-2019 ($ MILLIONS)
CHAPTER 8 MARKETS IN JAPAN
FIGURE 61 ASD PREVALENCE RATES IN JAPAN, 2000-2013 (PER 10,000 PEOPLE)
TABLE 62 JAPANESE ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
FIGURE 62 JAPANESE ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
THERAPEUTICS MARKET
OVERVIEW
ASD THERAPEUTICS MARKET IN JAPAN BY THERAPEUTIC CLASS
TABLE 63 JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ THOUSANDS)
FIGURE 63 JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ THOUSANDS)
Antipsychotics
TABLE 64 JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
FIGURE 64 JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013 ($ THOUSANDS)
Psychostimulants
TABLE 65 JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
FIGURE 65 JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
Antidepressants
TABLE 66 JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
FIGURE 66 JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS,
2013-2019 ($ THOUSANDS)
Antiepileptics
TABLE 67 JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
FIGURE 67 JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013 ($ THOUSANDS)
Antihypertensives
TABLE 68 JAPANESE ANTIHYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
FIGURE 68 JAPANESE ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
Sleep Medications
TABLE 69 JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
FIGURE 69 JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
Other
TABLE 70 JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
FIGURE 70 JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
JAPANESE ASD DIAGNOSTICS MARKET
OVERVIEW
MARKET
FORECAST
TABLE 71 JAPANESE ASD DIAGNOSTICS MARKET, THROUGH 2019 ($ MILLIONS)
FIGURE 71 JAPANESE ASD DIAGNOSTICS MARKET, 2013-2019 ($ ILLIONS)
CHAPTER 9 PIPELINE ASSESSMENT
OVERVIEW
STRATEGIC PIPELINE ASSESSMENT
PIPELINE ANALYSIS BY PHASE OF DEVELOPMENT
PHASE III CLINICAL PIPELINE
TABLE 72 NUMBER OF PHASE III CLINICAL TRIALS BY COUNTRY, 2014
PHASE II CLINICAL PIPELINE
TABLE 73 NUMBER OF PHASE II CLINICAL TRIALS BY COUNTRY, 2014
PHASE I CLINICAL PIPELINE
TABLE 74 NUMBER OF PHASE I CLINICAL TRIALS BY COUNTRY, 2014
PIPELINE BY MECHANISM OF ACTION
TABLE 75 NUMBER OF CLINICAL TRIALS BY MECHANISM OF ACTION, 2014
CLINICAL PIPELINE BY INDICATION
TABLE 76 NUMBER OF CLINICAL TRIALS BY INDICATION, 2014
CLINICAL PIPELINE BY PHENOTYPES OF ASD
TABLE 77 NUMBER OF CLINICAL TRIALS BY PHENOTYPES OF ASD BY COUNTRY, 2014
TECHNOLOGICAL TRENDS AND ANALYTICAL FRAMEWORK
MOST PROSPECTIVE DRUG PROFILES
NNZ-2566
Overview
Efficacy
Safety
Clinical Study Details
Phase I Clinical Trial
Phase II Clinical Trial
TABLE 78 TARGET DRUG PROFILE: NNZ-2566
CM-AT
Overview
Efficacy
Safety
Clinical Trial Details
Phase III Clinical Trials
TABLE 79 TARGET DRUG PROFILE: CM-AT
RG-7314
Overview
Efficacy
Safety
Clinical Trial Details
Phase II Clinical Trials
Phase I Clinical Trials
TABLE 80 TARGET DRUG PROFILE: RG7314
LATUDA
Overview
Efficacy
Safety
Clinical Trial Details
Phase III Clinical Trials
TABLE 81 TARGET DRUG PROFILE: LATUDA
CHAPTER 10 DIAGNOSTIC TECHNOLOGIES: RECENT DEVELOPMENTS
MARKET-ENTRY PRODUCTS
ARISK2
Description
Technology Value Appraisal
Technology Validity and Utility
Innovation and Reimbursement Strategy
Cost/comparative Effectiveness
NEXTSTEP
Description
Technology Value Appraisal
Technology Validity and Utility
Innovation and Reimbursement Strategy
Cost/Comparative Effectiveness
COMBISNP
Description
Technology Value Appraisal
Technology Validity and Utility
Innovation and Reimbursement Strategy
Cost/Comparative Effectiveness
DEVACT AND DEVSEEK
Description
Technology Value Appraisal
Technology Validity and Utility
Innovation and Reimbursement Strategy
Cost/Comparative Effectiveness
COMPARATIVE EVALUATION FOR MARKET-ENTRY PRODUCTS
TABLE 82 MARKET VALUE ESTIMATES OF FOUR MARKET-ENTRY ASD DIAGNOSTIC
PRODUCTS
IN THE PIPELINE
SDX-002
Developmental Phase
Technology Value Appraisal
CHAPTER 11 COMPANY PROFILES
THERAPEUTICS
ABBVIE INC.
ALCOBRA LTD.
APOTEX INC.
ASTRAZENECA PLC.
AUTISM THERAPEUTICS
AVANIR PHARMACEUTICALS INC.
BOEHRINGER INGELHEIM
CORONADO BIOSCIENCES, INC.
CUREMARK LLC
ELI LILLY & CO.
F. HOFFMANN-LA ROCHE AG
FOREST LABORATORIES INC.
GLAXOSMITHKLINE
JANSSEN PHARMACEUTICALS INC.
MALLINCKRODT PHARMACEUTICALS
MARINUS PHARMACEUTICALS INC.
NEUREN PHARMACEUTICALS LTD.
NOVARTIS PHARMA SERVICES AG
OTSUKA PHARMACEUTICALS
PFIZER INC.
PHARMACIA & UPJOHN LLC
SUNOVION PHARMACEUTICALS INC.
DIAGNOSTICS
AMBRY GENETICS
ATHENA DIAGNOSTICS
COMBIMATRIX CORP.
COURTAGEN LIFE SCIENCES INC.
GENEDX
INTEGRAGEN
LINEAGEN INC.
SYNAPDX
TRANSGENOMIC INC.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report